Cancer-associated marantic endocarditis: a rare but relevant complication
European Heart Journal - Cardiovascular Imaging · 2023
DOI: 10.1093/ehjci/jead162 ↗Kurz gefasst
Editorial in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2023. Verfasst von Csilla Celeng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. Hauptthemen laut MEDLINE: Endocarditis, Non-Infective, Neoplasms, Endocarditis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
This editorial refers to ‘Multimodality imaging in marantic endocarditis associated with cancer: a multicentric cohort study’, by F. Deharo et al., https://doi.org/10.1093/ehjci/jead139. In this issue of European Heart Journal—Cardiovascular Imaging, Deharo et al.1 published a retrospective observational article on marantic endocarditis (ME) using multi-modality imaging. ME is also known as Libman–Sacks endocarditis, non-infectious endocarditis, or non-bacterial thrombotic endocarditis. The study included 47 individuals with ME and cancer. ME was initially diagnosed by echocardiography. Not surprisingly, no abscess or pseudoaneurysm was observed, since these are most commonly caused by an infectious/inflammatory mechanism. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) was performed in 30 patients; all had no increased valvular uptake. PET imaging identified cancer (lung and pancreas among the most common) in 14 individuals. Contrast-enhanced computed tomography (CT) was performed in 42 patients and detected systemic embolization in 40 individuals (central nervous system, splenic, and renal). Infectious cause was excluded using blood cultures. In 46% of patients, the diagnosis of cancer was already known before ME was found, and in 54%, cancer was diagnosed after endocarditis was observed. Forty-one patients were treated with anticoagulation therapy and six patients underwent valvular surgery. Length of stay for hospitalization was not reported but would have been likely confounded by the presence of cancer. Both in-hospital mortality and one-year mortality were high, 31% and 55%, respectively. Poor outcomes for patients with ME and cancer have also been confirmed by others, with a 1-year mortality rate of 33%.2 To what degree the relatively high number of deaths is predominantly caused by cancer or is related to ME remains unclear. The prevalence of ME in patients with cancer was reported to be 19%, 10 times higher compared to controls.3 Available data suggest that ME can occur in patients with a hypercoagulable state (cancer, systemic lupus erythematosus, and antiphospholipid syndrome), resulting in endothelial injury of the valves and consequent thrombus formation.4 ME is mostly discovered post-mortem with a prevalence of about 0.9–1.6% and most commonly affects those between the ages of 40 to 80 without a predilection for sex.4 In the current study, 54% of the patients were male.1 Due to its rare nature, most literature is limited to observational studies. Current guidelines do not incorporate the diagnosis and treatment of ME. The strength of the current observational study is that it reflects a real-world experience, where the diagnosis of ME was established by a dedicated endocarditis team. A firm diagnosis however can only be made by the demonstration of non-infected platelet thrombi on histological specimens, which in this study was limited to six individuals who underwent valvular surgery. Morphologically ME is characterized by valvular thickening, which can range from microscopic fibrine deposits to large vegetations on previously intact heart valves in a sterile microenvironment. Most commonly, as in the current study, aortic and mitral valves are involved.4 Patients are usually asymptomatic, though these valvular abnormalities can lead to regurgitation and cerebrovascular or systemic embolism. The hallmarks of ME can be detected by using similar imaging techniques and recommendations as in those with infective endocarditis.5 Echocardiography is non-invasive, radiation free, and easily accessible and as such plays a central role in the evaluation of heart valves. The sensitivity for the detection of a vegetation is around 75% for transthoracic echocardiography and 85–90% for transesophageal echocardiography.6 Echocardiography allows for evaluating the size, mobility, and evolution of the vegetation.7 Specific features like small ‘kissing’ vegetations seem pathognomonic for ME of the aortic valve.8 CT has a comparable diagnostic accuracy for detecting valvular abnormalities to echocardiography.9 In addition, CT is highly effective in diagnosing potential systemic embolisms. 18F-FDG PET/CT allows for the identification of tissues with elevated glucose metabolism. The absence of increased valvular uptake on 18F-FDG-PET/CT does not definitively exclude infectious valve endocarditis, but the presence of elevated uptake strongly indicates an infectious cause.7,10 Moreover, 18F-FDG PET/CT is well suited for identifying cancer, especially of head and neck cancer, lung cancer, and pancreatic cancer and for unknown primary tumour.11 In conclusion, based on the current study and previous literature physicians should be aware of ME as a potential complication in patients with cancer. ME is a challenging clinical diagnosis, especially since blood cultures are only helpful to exclude an infective cause. Evaluation by an endocarditis team (including cardiologists and radiologists) is helpful in the diagnosis of this rare condition. If ME is suspected, echocardiography should be used primarily. Contrast enhanced CT is able to detect systemic embolization and 18F-FDG PET/CT can aid the diagnosis of ME as well as identify cancer of unknown origin. The medical management of patients with ME lacks clear guidelines, partly due to limited information on the natural course of the disease in untreated patients.4,12 While it is crucial to treat the underlying disease, anticoagulant therapy should be considered in patients who experienced a thromboembolic event. In case of significant valvular dysfunction, surgery can be performed. Since the disease is non-infectious, preservation of the native valves may be possible.13 None declared. No new data were generated or analysed in support of this research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Location AMC, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.
ORCID-Profile: Richard A P Takx
Zitieren
APA
Celeng, C., & Takx, R. A. P. (2023). Cancer-associated marantic endocarditis: a rare but relevant complication. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead162
Vancouver
Celeng C, Takx RAP. Cancer-associated marantic endocarditis: a rare but relevant complication. European Heart Journal - Cardiovascular Imaging. 2023. doi:10.1093/ehjci/jead162
BibTeX
@article{Celeng2023,
author = {Celeng, Csilla and Takx, Richard A P},
title = {Cancer-associated marantic endocarditis: a rare but relevant complication},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2023},
doi = {10.1093/ehjci/jead162}
}
EUVIMED